OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions Oct 24, 2018
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer Oct 15, 2018
OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc. Oct 9, 2018
Data from OncoSec's OMS-100 Clinical Trial Accepted for Oral Presentation at the 2018 Melanoma Bridge Conference Oct 2, 2018
